DNA mutations are key hallmarks of cancer, with the identity of mutated genes — such as KRAS, BRAF, and PIK3CA — playing a critical role in therapy selection and disease monitoring.

However, mutation detection currently requires specialized equipment and trained personnel, making it time-consuming, costly, and largely confined to specialized laboratories, which limits widespread accessibility.

To address this challenge, we have developed a novel technology that captures target sequences on beads, followed by fluorescence detection using flow cytometry.

Our platform enables sensitive detection of cancer-related mutations (e.g., KRAS, TP53, PIK3CA) from plasma and tissue samples, with a limit of detection as low as 27 femtomolar (fM). By detecting both normal and mutated gene variants concurrently, it quantifies the mutation frequency within the sample.

The technology supports simultaneous detection of multiple mutations in a single test (multiplexing).